Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

NB003

Stage Phase 2/3

Sponsor Ningbo Newbay Technology Development

Route oral

Modality small molecule

Class selective KIT TKI

Mechanism potent and selective oral small-molecule KIT inhibitor (sponsor description)

Target KIT (TEC-0117)

Sources

publication, as of 2026-11-07

https://www.esmoopen.com/article/S2059-7029(26)01903-4/fulltext

By March 2025, among 158 GIST pts in the 2nd line to >= 4th line therapies, ORR was 28.5%, DoR 11.5 months, DCR 77.8% and PFS 9.2 months. Significantly, the pts in third-line therapy showed ORR 46.7%, DoR 12 months, DCR 90% and PFS 13.7 months. ... NB003 is administrated at 15 mg BID

ESMO Open 157TiP (2026), GISTAR-1 design (NCT07379047)

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT04936178

A Multicenter Phase 1, Open-Label Study of NB003 to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Malignancies

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07379047

A Multicenter, Open-label Clinical Study to Evaluate the Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NB003 Phase 1

Registry NCT04936178

Phase Phase 1

Status Completed

Enrollment 258

Start 2021-08-06

Primary completion 2025-08-01

Study completion 2025-08-01

NB003, 2L to 4L or later

Dose not stated in source

Population GIST 2L to 4L or later (n = 158)

Estimand Single arm

objective response rate: 28.5%, data as of March 2025

median progression-free survival: 9.2 months, data as of March 2025

NB003, 3L subgroup

Dose not stated in source

Population GIST 3L (n not stated in source)

Estimand Single arm

objective response rate: 46.7%, data as of March 2025

median progression-free survival: 13.7 months, data as of March 2025

GISTAR-1

Registry NCT07379047

Phase Phase 2/3

Status Recruiting

Enrollment 255

Start 2026-05-11

Primary completion 2028-08-01

Study completion 2028-09-01

Catalyst Primary completion. 08.01.2028. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

NB003 15 mg BID (Part 1)

Dose 15 mg

Regimen twice daily

Comparator regorafenib 160 mg

Population 3L GIST after imatinib and sunitinib

Estimand ITT

Regorafenib 160 mg

Dose 160 mg

Regimen once daily

Population 3L GIST

Estimand ITT